Relief Therapeutics Receives Notice of Allowance for European Patent Covering RLF-TD011 for Epidermolysis Bullosa Wound Treatment ...

Relief Therapeutics (OTCQB:RLFTY) Wednesday reported the formation of its new executive committee, with the appointment of several new members, including a chief financial officer, chief human ...

Relief Therapeutics Announces Promising Preliminary Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa ...

If you are thinking of buying or selling Relief Therapeutics Holding stock, you should check out this FREE detailed report on ...

GENEVA (SEPT. 23, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for ...

GENEVA, SWITZERLAND / ACCESSWIRE / September 18, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...

Relief Therapeutics to receive European patent covering RLF-TD011 for epidermolysis bullosa wound treatment: Geneva Tuesday, October 22, 2024, 13:00 Hrs [IST] Relief Therapeutics ...

GENEVA, SWITZERLAND / ACCESSWIRE / October 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to ...

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic ...

Relief Therapeutics Holding SA, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic ...